Aneta Rotterova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aneta Rotterova has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Kamil Musilek
Department of Chemistry, Faculty of Science University of Hradec Kralove Hradec Kralove Czech Republic
2 shared publications - Lucie Zemanova
University of Hradec Kralove, Faculty of Science, Department of Chemistry, Rokitanskeho 62, 500 03 Hradec Kralove, Czech Republic
2 shared publications - Monika Schmidt
University of Hradec Kralove, Faculty of Science, Department of Chemistry, Rokitanskeho 62, 500 03 Hradec Kralove, Czech Republic
2 shared publications - Ondrej Benek
Faculty of Science, Department of Chemistry, University of Hradec Kralove, Rokitanskeho 62, 500 03 Hradec Kralove, Czech Republic
2 shared publications - Ivo Fabrik
Biomedical Research Center, University Hospital Hradec Kralove
1 shared publication - Marketa Sedlacek Miskerikova
Faculty of Science, Department of Chemistry, University of Hradec Kralove, Rokitanskeho 62, 500 03 Hradec Kralove, Czech Republic
1 shared publication
Latest Publications
- Open Access
New insights into the 17β-hydroxysteroid dehydrogenase type 10 and amyloid-β 42 derived cytotoxicity relevant to Alzheimer’s disease
The multifunctional mitochondrial enzyme 17β-hydroxysteroid dehydrogenase type 10 (HSD10) plays an important role in the pathology of several diseases, of which Alzheimer’s disease (AD) is the most debated. HSD10 overexpression and its interplay with amyloid-β peptide (Aβ) are considered a factor contributing to mitochondrial damage and neuronal stress observed in AD patients. This study confirms that individual overexpression of HSD10 or APP (amyloid precursor protein that gives rise to Aβ) leads to cytotoxicity, and both pathological conditions are linked to mitochondrial damage. However, the metabolic changes caused by these two overexpressions significantly differ, particularly in their effect on the tricarboxylic acid cycle and β-oxidation. Furthermore, the enzymatic activity of HSD10 is identified as the primary factor of HSD10 cytotoxicity, which is significantly exacerbated in an Aβ-rich environment and can be partially reversed by HSD10 inhibitors. Notably, a previously published and competitive benzothiazole inhibitor was effective in restoring the viability of HSD10 overexpressing cells alone and in an Aβ-rich environment, implying the potential benefit of HSD10 inhibitors in mitochondrial diseases and/or AD treatment. GRAPHICAL
Open AccessNew insights into the 17β-hydroxysteroid dehydrogenase type 10 and amyloid-β 42 derived cytotoxicity relevant to Alzheimer’s disease
The multifunctional mitochondrial enzyme 17β-hydroxysteroid dehydrogenase type 10 (HSD10) plays an important role in the pathology of several diseases, of which Alzheimer’s disease (AD) is the most debated. HSD10 overexpression and its interplay with amyloid-β peptide (Aβ) are considered a factor contributing to mitochondrial damage and neuronal stress observed in AD patients. This study confirms that individual overexpression of HSD10 or APP (amyloid precursor protein that gives rise to Aβ) leads to cytotoxicity, and both pathological conditions are linked to mitochondrial damage. However, the metabolic changes caused by these two overexpressions significantly differ, particularly in their effect on the tricarboxylic acid cycle and β-oxidation. Furthermore, the enzymatic activity of HSD10 is identified as the primary factor of HSD10 cytotoxicity, which is significantly exacerbated in an Aβ-rich environment and can be partially reversed by HSD10 inhibitors. Notably, a previously published and competitive benzothiazole inhibitor was effective in restoring the viability of HSD10 overexpressing cells alone and in an Aβ-rich environment, implying the potential benefit of HSD10 inhibitors in mitochondrial diseases and/or AD treatment. GRAPHICAL
- 17 July 2023
- Published by Wiley in Journal of Neurochemistry
- Vol. 167 (2) , 154-167
Physiologically relevant fluorescent assay for identification of 17β‐hydroxysteroid dehydrogenase type 10 inhibitors
Mitochondrial enzyme 17β‐hydroxysteroid dehydrogenase type 10 (HSD10) is a potential molecular target for treatment of mitochondrial‐related disorders such as Alzheimer's disease (AD). Its over‐expression in AD brains is one of the critical factors disturbing the homeostasis of neuroprotective steroids and exacerbating amyloid beta (Aβ)‐mediated mitochondrial toxicity and neuronal stress. This study was focused on revalidation of the most potent HSD10 inhibitors derived from benzothiazolyl urea scaffold using fluorescent‐based enzymatic assay with physiologically relevant substrates of 17β‐oestradiol and allopregnanolone. The oestradiol‐based assay led to the identification of two nanomolar inhibitors (IC50 70 and 346 nM) differing from HSD10 hits revealed from the formerly used assay. Both identified inhibitors were found to be effective also in allopregnanolone‐based assay with non‐competitive or uncompetitive mode of action. In addition, both inhibitors were confirmed to penetrate the HEK293 cells and they were able to inhibit the HSD10 enzyme in the cellular environment. Both molecules seem to be potential lead structures for further research and development of HDS10 inhibitors. image
- 17 July 2023
- Published by Wiley in Journal of Neurochemistry
- Vol. 167 (2) , 154-167
Physiologically relevant fluorescent assay for identification of 17β‐hydroxysteroid dehydrogenase type 10 inhibitors
Mitochondrial enzyme 17β‐hydroxysteroid dehydrogenase type 10 (HSD10) is a potential molecular target for treatment of mitochondrial‐related disorders such as Alzheimer's disease (AD). Its over‐expression in AD brains is one of the critical factors disturbing the homeostasis of neuroprotective steroids and exacerbating amyloid beta (Aβ)‐mediated mitochondrial toxicity and neuronal stress. This study was focused on revalidation of the most potent HSD10 inhibitors derived from benzothiazolyl urea scaffold using fluorescent‐based enzymatic assay with physiologically relevant substrates of 17β‐oestradiol and allopregnanolone. The oestradiol‐based assay led to the identification of two nanomolar inhibitors (IC50 70 and 346 nM) differing from HSD10 hits revealed from the formerly used assay. Both identified inhibitors were found to be effective also in allopregnanolone‐based assay with non‐competitive or uncompetitive mode of action. In addition, both inhibitors were confirmed to penetrate the HEK293 cells and they were able to inhibit the HSD10 enzyme in the cellular environment. Both molecules seem to be potential lead structures for further research and development of HDS10 inhibitors. image